Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “febuxostat” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 16
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 16 pipeline programs matching "febuxostat" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

16 results for “febuxostat” Back to intelligence hub

Search results

  1. Febuxostat

    Takeda

    Cardiovascular Disease

    phase 3 small molecule completed

    1 trial
  2. Febuxostat IR

    Takeda

    Gout

    phase 3 small molecule completed

    2 trials
  3. FEBUXOSTAT, ALLOPURINOL

    Pari Pharma GmbH

    Gout adult patients

    phase 2 small molecule active

    1 trial
  4. Febuxostat

    Takeda

    Hypertension

    phase 2 small molecule completed

    1 trial
  5. Febuxostat

    Takeda

    Angina

    phase 2 small molecule terminated

    1 trial
  6. Febuxostat

    Takeda

    Hyperuricosuria

    phase 2 small molecule completed

    1 trial
  7. Febuxostat

    Takeda

    Joint Damage

    phase 2 small molecule completed

    1 trial
  8. Febuxostat

    Takeda

    Renal Impairment

    phase 2 small molecule completed

    1 trial
  9. Febuxostat XR

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  10. Febuxostat XR

    Takeda

    Gout

    phase 1 small molecule completed

    1 trial
  11. Febuxostat XR 80 mg Capsule F1

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  12. 20mg Febuxostat

    The First People's Hospital of Lianyungang

    Hyperuricemia

    approved small molecule active

    1 trial
  13. Febuxostat

    Takeda

    Gout

    approved small molecule completed

    6 trials
  14. Febuxostat

    Takeda

    Coronary Artery Disease

    approved small molecule completed

    1 trial
  15. Febuxostat

    Takeda

    Chronic Kidney Disease

    small molecule completed

    1 trial
  16. Febuxostat

    The First People's Hospital of Lianyungang

    Refractory Gout

    small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.